FDA Drug Safety Communication: Eosinophilic pneumonia associated with the use of Cubi
| Title: | FDA Drug Safety Communication: Eosinophilic pneumonia associated with the use of Cubi |
| URL: | http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProv |
| Description: | [07-29-2010] The U.S. Food and Drug Administration (FDA) is informing patients and healthcare professionals about the potential for developing eosinophilic pneumonia during treatment with Cubicin (daptomycin), an intravenous antibacterial drug." " |
| Page Rank: | 0 |